F. Matzkies

Effect of Filgotinib vs Placebo on Clinical Response in Patients With Moderate to Severe Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy

Mark C. Genovese, Kenneth Kalunian, Jacques‐Eric Gottenberg et al. · JAMA · 2019 · 305 citations · Full text

Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial

Bernard Combe, Alan Kivitz, Yoshiya Tanaka et al. · Annals of the Rheumatic Diseases · 2021 · 228 citations · Full text

Filgotinib in combination with methotrexate or as monotherapy versus methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: the phase 3, randomised controlled FINCH 3 trial

René Westhovens, William F. C. Rigby, Désirée van der Heijde et al. · Annals of the Rheumatic Diseases · 2021 · 134 citations · Full text

Integrated safety analysis of filgotinib in patients with moderately to severely active rheumatoid arthritis receiving treatment over a median of 1.6 years

Kevin Winthrop, Yoshiya Tanaka, Tsutomu Takeuchi et al. · Annals of the Rheumatic Diseases · 2021 · 78 citations · Full text

Safety and efficacy of filgotinib, lanraplenib and tirabrutinib in Sjögren’s syndrome: a randomized, phase 2, double-blind, placebo-controlled study

Elizabeth Price, Alan Kivitz, F. Matzkies et al. · Lara D. Veeken · 2022 · 66 citations · Full text